Recent Publications

Basic Science

  1. Inhibition of eIF2alpha dephosphorylation inhibits ErbB2-induced deregulation of mammary acinar morphogenesis. Sequeira SJ, Wen HC, Avivar-Valderas A, Farias EF, Aguirre-Ghiso JA. BMC Cell Biol. 2009 Sep 15;10:64.
  2. On the theory of tumor self-seeding: implications for metastasis progression in humans. Aguirre-Ghiso JA. Breast Cancer Res. 2010;12(2):304.
  3. Dormancy of metastatic melanoma. Ossowski L, Aguirre-Ghiso JA. Pigment Cell Melanoma Res. 2010 Feb;23(1):41-56.
  4. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Adam AP, George A, Schewe D, Bragado P, Iglesias BV, Ranganathan AC, Kourtidis A, Conklin DS, Aguirre-Ghiso JA. Cancer Res. 2009 Jul 15;69(14):5664-72.
  5. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Schewe DM, Aguirre-Ghiso JA. Cancer Res. 2009 Feb 15;69(4):1545-52.
  6. Inhibition of eIF2alpha dephosphorylation inhibits ErbB2-induced deregulation of mammary acinar morphogenesis. Sequeira SJ, Wen HC, Avivar-Valderas A, Farias EF, Aguirre-Ghiso JA. BMC Cell Biol. 2009 Sep 15;10:64.
  7. ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Schewe DM, Aguirre-Ghiso JA. Proc Natl Acad Sci USA. 2008 Jul 29;105(30):10519-24.
  8. Ribonomic and short hairpin RNA gene silencing methods to explore functional gene programs associated with tumor growth arrest. Baroni TE, Lastro MT, Ranganathan AC, Tenenbaum SA, Conklin DS, Aguirre-Ghiso JA. Methods Mol Biol. 2007;383:227-44.
  9. A. Sikora, N. Jaffarzad, Y. Hailemichael, A. Gelbard, S. Stonier, K. Schluns, L. Frasca, Y. Lou, C. Liu, H. Andersson, P. Hwu, W. Overwijk. Interferon-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and anti-tumor activity. Journal of Immunology 2009; 182: 7398-7407.
  10. A. Sikora, A. Gelbard, M. Davies, D. Sano, S. Ekmekcioglu, J. Kwon, Y. Hailemichael, P. Jayaraman, J. Myers, E. Grimm, W. Overwijk. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clinical Cancer Research 2010; 16(6): 1834-44.
  11. H. Vu, A. Sikora, S. Fu, J. Kao. HPV-Induced Oropharyngeal Cancer, Immune Response, and Response to Therapy. Cancer Letters 2009; (in press; doi:10.1016/j.canlet.2009.06.026).
  12. J. Kao, A. Sikora, S. Fu. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Current Cancer Drug Targets 2009; 9:931-937.
  13. J. Kao, E.C. Ko, S. Eisenstein, A.G. Sikora, S. Fu, S.H. Chen. Targeting Immune Suppressing Myeloid-Derived Suppressor Cells In Oncology. Critical Reviews in Oncology and Hematology 2010 (March 19 epub ahead of print).

Clinical

  1. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.Kao J, Genden EM, Gupta V, Policarpio EL, Burri RJ, Rivera M, Gurudutt V, Som PM, Teng M, Packer SH. Cancer. 2010 Sep 9.
  2. Herpes simplex virus oncolytic vaccine therapy in melanoma. Sivendran S, Pan M, Kaufman HL, Saenger Y. Expert Opin Biol Ther. 2010 Jul;10(7):1145-53.
  3. Papanicolaou stain may not be necessary in majority of head and neck fine-needle aspirations: Evidence from a correlation study between Diff-Quik-based onsite diagnosis and final diagnosis in 287 head and neck fine-needle aspirations. Wu M, Idrees M, Zhang Z, Genden E, Burstein DE. Diagn Cytopathol. 2010 Mar 18.
  4. Feasibility of immunocytochemical detection of tumor markers (XIAP, phosphohistone H1 and p63) in FNA cellblock samples from head and neck squamous cell carcinoma. Wu M, Kafanas A, Gan L, Kohtz DS, Zhang L, Genden E, Burstein DE. Diagn Cytopathol. 2008 Nov;36(11):797-800.
  5. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Kao J, Sikora AT, Fu S.Curr Cancer Drug Targets. 2009 Dec;9(8):931-7.
  6. HPV-induced oropharyngeal cancer, immune response and response to therapy.Vu HL, Sikora AG, Fu S, Kao J.Cancer Lett. 2010 Feb 28;288(2):149-55. Epub 2009 Jul 22.
  7. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer.Kao J, Vu HL, Genden EM, Mocherla B, Park EE, Packer S, Som PM, Kostakoglu L. Cancer. 2009 Oct 1;115(19):4586-94.
  8. Bidirectional association of anogenital and oral cavity/pharyngeal carcinomas in men. Sikora AG, Morris LG, Sturgis EM. Arch Otolaryngol Head Neck Surg. 2009 Apr;135(4):402-5.
  9. The significance and management of incidental [18F]fluorodeoxyglucose-positron-emission tomography uptake in the thyroid gland in patients with cancer. Eloy JA, Brett EM, Fatterpekar GM, Kostakoglu L, Som PM, Desai SC, Genden EM. AJNR Am J Neuroradiol. 2009 Aug;30(7):1431.
  10. L. Morris, A.R. Shaha, R.M. Tuttle, A.G. Sikora, I. Ganly. Tall cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid (in press).
  11. A. Sikora, Y. Shnayder, H. Yee, M. DeLacure. Oropharyngeal Kaposi Sarcoma In Related HIV-Negative Individuals, Annals of Otology, Rhinology, and Laryngology 2008; 117:172-176.
  12. L. Morris, A. Sikora, D. Myssiorek, M. DeLacure. The basis of racial differences in the incidence of thyroid cancer. Annals of Surgical Oncology 2008; 15:1169-1176.

Other Clinical Publications

  1. Facial transplantation: the next frontier in head and neck reconstruction. Park EE, Genden EM. Facial Plast Surg Clin North Am. 2009 May;17(2):271-7.
  2. Reconstruction of the mandible and the maxilla: the evolution of surgical technique.Genden EM.Arch Facial Plast Surg. 2010 Mar-Apr;12(2):87-90.
  3. Contemporary management of cancer of the oral cavity.Genden EM, Ferlito A, Silver CE, Takes RP, Suárez C, Owen RP, Haigentz M Jr, Stoeckli SJ, Shaha AR, Rapidis AD, Rodrigo JP, Rinaldo A. Eur Arch Otorhinolaryngol. 2010 Jul;267(7):1001-17.
  4. Transoral robotic surgery using a carbon dioxide flexible laser for tumors of the upper aerodigestive tract.Desai SC, Sung CK, Jang DW, Genden EM.Laryngoscope. 2008 Dec;118(12):2187-9.
  5. Transoral robotic surgery using an image guidance system. Desai SC, Sung CK, Genden EM.Laryngoscope. 2008 Nov;118(11):2003-5.
  6. The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer. Adappa ND, Sung CK, Choi B, Huang TG, Genden EM, Shin EJ. Otolaryngol Head Neck Surg. 2008 Sep;139(3):442-8.
  7. Palliative care for patients with head and neck cancer: "I would like a quick return to a normal lifestyle".Goldstein NE, Genden E, Morrison RS. JAMA. 2008 Apr 16;299(15):1818-25.
  8. Correlation of positron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck. Burri RJ, Rangaswamy B, Kostakoglu L, Hoch B, Genden EM, Som PM, Kao J.Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):682-8.
  9. Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: an analysis by primary site and nodal stage. Kao J, Lavaf A, Teng MS, Huang D, Genden EM. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):362-70.
  10. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Lavaf A, Genden EM, Cesaretti JA, Packer S, Kao J. Cancer. 2008 Feb 1;112(3):535-43.
  11. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Sung CK, Choi B, Wanna G, Genden EM, Woo SL, Shin EJ. Laryngoscope. 2008 Feb;118(2):237-42.
  12. Vessel-depleted neck: techniques for achieving microvascular reconstruction. Jacobson AS, Eloy JA, Park E, Roman B, Genden EM. Head Neck. 2008 Feb;30(2):201-7.
  13. Recent changes in the treatment of patients with advanced laryngeal cancer. Genden EM, Ferlito A, Rinaldo A, Silver CE, Fagan JJ, Suárez C, Langendijk JA, Lefebvre JL, Bradley PJ, Leemans CR, Chen AY, Jose J, Wolf GT. Head Neck. 2008 Jan;30(1):103-10.
  14. Concurrent chemotherapy and radiotherapy for head and neck cancer. Burri RJ, Lee NY. Expert Rev Anticancer Ther. 2009 Mar;9(3):293-302. Review.
  15. The evolution of management for inverted papilloma: an analysis of 200 cases. Lawson W, Patel ZM. Otolaryngol Head Neck Surg. 2009 Mar;140(3):330-5.
  16. Transoral robotic assisted free flap reconstruction. Mukhija VK, Sung CK, Desai SC, Wanna G, Genden EM. Otolaryngol Head Neck Surg. 2009 Jan;140(1):124-5.
  17. Selective neck dissection following adjuvant therapy for advanced head and neck cancer. Mukhija V, Gupta S, Jacobson AS, Anderson Eloy J, Genden EM. Head Neck. 2009 Feb;31(2):183-8.
  18. Transoral robotic surgery for the management of head and neck cancer: a preliminary experience. Genden EM, Desai S, Sung CK. Head Neck. 2009 Mar;31(3):283-9.
  19. High uptake in schneiderian papillomas of the maxillary sinus on positron-emission tomography using fluorodeoxyglucose. Lin FY, Genden EM, Lawson WL, Som P, Kostakoglu L. AJNR Am J Neuroradiol. 2009 Feb;30(2):428-30. Epub 2008 Sep 3.
  20. Brachial plexus neuropathy resulting from a massively enlarged papillary thyroid carcinoma. Lipana JD, Teng MS. Laryngoscope. Aug;119(8):1550-1.
  21. Fine-needle aspiration biopsy of granular cell tumor of the tongue:a technique for the aspiration of oral lesions. Fitzhugh VA, Maniar KP, Gurudutt VV, Rivera M, Chen H, We M. Diagn Cytopathol. 2009Nov:37(11): 839-42.
  22. Vacuum-assisted closure therapy in the management of head and neck wounds.Dhir K, Reino AJ, Lipana J.Laryngoscope. 2009 Jan;119(1):54-61.
  23. Selective neck dissection following adjuvant therapy for advanced head and neck cancer.Mukhija V, Gupta S, Jacobson AS, Anderson Eloy J, Genden EM.Head Neck. 2009 Feb;31(2):183-8.